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Abstract:
Background: Most studies investigating antipsychotic effectiveness re-
port either total psychopathology or symptom cluster findings. Studies fo-
cusing on a separate symptom, such as hallucinations, a hallmark symptom
in schizophrenia, are scarce.
Therefore, the current study aims to compare the antihallucinatory
effectiveness of 3 pharmacologically different antipsychotics: olanzapine,
amisulpride, and aripiprazole.
Methods: The present study is part of the Bergen-Stavanger-Innsbruck-
Trondheim study, a 12-month prospective, randomized, pragmatic antipsy-
chotic drug trial in active-phase schizophrenia spectrum disorders. The primary
outcome of the present study was change of hallucinations as measured by
item P3 (hallucinatory behavior) from the Positive and Negative Syndrome
Scale in the subgroup with hallucinations at baseline. Primary analyses
were intention to treat.
Results: A total of 144 participants were included in the study, where 105
(72%) had a score of 3 or more on the Positive and Negative Syndrome
Scale P3 item at baseline, indicating the presence of hallucinations (HALL
subgroup).
In the HALL subgroup, a significantly less reduction of hallucina-
tions was revealed for participants using olanzapine in weeks 12, 26, 39,
and 52 when compared with amisulpride and in weeks 26 and 52 when
compared with aripiprazole. In subanalyses for participants never exposed
to antipsychotic drugs (antipsychotic-naive) and those who had used anti-
psychotics before entering the study, antihallucinatory differences were re-
vealed only in the latter group.
Conclusions: A differential antihallucinatory effect of the 3 study drugs
was present. The inferior effect of olanzapine seems to be driven by the
subgroup of participants exposed to antipsychotic treatment before enter-
ing the study.
Key Words: antipsychotics, hallucinations, differential effectiveness,
randomized trial
(J Clin Psychopharmacol 2021;41: 389–396)
V ariability in the effectiveness of antipsychotic treatmentremains a major clinical challenge in the treatment of
schizophrenia-spectrum disorders.1 Whereas individually tailored
drug protocols are established in other medical disciplines, anti-
psychotic treatment is much less targeted, with a trial-and-error
approach often lasting from weeks to months and even years.2 The
consequence of this trial-and-error approach may be long-term
exposure to drugs without clear benefits and with possible risk
of reinforcing adverse effects, prolonged suffering, and adverse
impact on long-term prognosis because of sustained illness.2
Overall antipsychotic effectiveness is thoroughly documented.3
However, the focus in the majority of studies has been either
change of total psychopathology or clusters of symptom scores.3,4
This might conceal effectiveness differences between separate
symptoms of interest. Different symptoms might have, at least in
part, separate underlying psychopathology5 and combining them
might mask underlying differences. Because psychotic disorders
are symptomatically heterogeneous, revealing possible differences
among antipsychotics for separate symptoms would contribute
to understanding symptom-specific and personalized treatment.6
Hallucinations are one of the hallmark symptoms of schizo-
phrenia and related disorders. As much as 80% of patients experi-
ence hallucinations, where auditory hallucinations are reported
most frequently.7 Hallucinations in general and auditory verbal
hallucinations in particular are important treatment targets, being not
only a major burden to patients but might also lead to self-harm,
suicide, violence or homicide.8,9 Hallucinations respond well to
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antipsychotics, and the response is likely to appear rapidly.10,11 In
our previous study, we demonstrated that more than three-quarters
of patients with clinically significant hallucinations at baseline
reported vanishing of hallucinations during the first 4 weeks
of treatment.11 In a study with 362 patients with first-episode
(FEP) schizophrenia, Sommer et al10 found that hallucinations
were reduced to a level of minimal-mild already after 4 weeks of
treatment. After treatment with antipsychotics for 1 year, only 8%
still had mild to moderate hallucinations. The authors found that
olanzapine, amisulpride, ziprasidone, and quetiapine were equally
effective against hallucinations; however, haloperidol was found
to be slightly less effective.10 In our previous naturalistic random-
ized controlled trial comparing quetiapine, ziprasidone, risperi-
done, and olanzapine, differential effectiveness was found
among these second-generation antipsychotics for hallucinations.12
The quetiapine and ziprasidone groups had faster reductions of
mean hallucination scores compared with the risperidone group.
Symptom-specific differences among antipsychotic drugs accord-
ingly seem to exist, but empirical evidence is sparse. Diverse phar-
macological properties may underlie drug different effectiveness.
The common action of all antipsychotics is functional blockade of
striatal dopamine D2 receptors, but with varying potencies. Some
newer antipsychotics are partial agonist at the D2 receptors.13
Furthermore, affinity for nondopaminergic receptors vary sub-
stantially among drugs. Amisulpride has the cleanest receptor
profile, targeting mainly D2/D3 receptors with little effect on
other receptors. Olanzapine on the other hand binds tomultiple re-
ceptors including dopaminergic, serotonergic, histaminergic, ad-
renergic, and muscarinergic systems. Finally, aripiprazole shares
the broad receptor binding profile of most second-generation an-
tipsychotics, but is distinguished by its partial agonistic action at
the D2 receptor.
Also, antipsychotic treatment response in general might be
affected by several factors, where antipsychotic naivety and illness
duration are known modifiers of effect.14 Treatment response
seems to become less favorable for patients previously exposed
to antipsychotics and with increasing illness duration.14,15 The
current study therefore aimed at comparing the antipsychotic effec-
tiveness for hallucinations of 3 pharmacologically diverse antipsy-
chotics: olanzapine, amisulpride, and aripiprazole. A secondary
aim was to investigate any impact of previous antipsychotic expo-
sure on differential effectiveness among the study drugs.
METHODS
Study Design
The present study is part of the Bergen-Stavanger-Innsbruck-
Trondheim study (BeSt InTro; ClinicalTrials.org, number
NCT01446328).
TheBeSt InTro study aimed to compare 3 pharmacologically dif-
ferent antipsychotics—amisulpride, aripiprazole, and olanzapine—
in a prospective, randomized, pragmatic design. The study was
conducted between 2011 and 2017 at the Division of Psychiatry,
at HaukelandUniversity Hospital in Bergen, Stavanger University
Hospital in Stavanger, St Olavs Hospital, Trondheim, and at the
Medisinische Universität Innsbruck, Austria. The BeSt InTro
study was funded by The Research Council of Norway, the West-
ern Norway Regional Health Trust, and participating hospitals
and universities and did not receive any financial or other support
from the pharmaceutical industry. The study was approved in
Norway by the Regional Committees for Medical and Health Re-
search Ethics, and the Norwegian Medicines Agency, and in
Austria by the Etikkommission der Medizinische Universität
Innsbruck, and the Austrian Federal Office for Safety in Health
Care (BASG). Further details can be found in the previous publi-
cation of the primary outcome.16 The data presented here repre-
sent secondary outcomes in the BeSt InTro trial.
Participants
A total of 144 participants aged ≥18 years with active psy-
chosis symptoms as determined by a score of ≥4 on one or more
of the following Positive and Negative Syndrome Scale (PANSS)
items: P1 (delusions), P3 (hallucinatory behavior), P5 (grandios-
ity), P6 (suspiciousness/persecution) or G9 (unusual thought con-
tent)17 were included in the present study.
Participants were excluded if they were not able to use oral
drugs, did not understand the native language, were hypersensitive
to the active substances or to any of the excipients of the study
drugs, and had prolactin-dependent tumors (eg, pituitary gland
prolactinomas and breast cancer), pheochromocytoma in com-
bination with medications that could induce torsade de pointes,
and a known risk of narrow-angle glaucoma. All included par-
ticipants had a diagnosis within the schizophrenia spectrum
(F20–29) as defined in the International Classification of Disease,
Tenth Revision.18 After participants signed an informed consent
form, they were randomized to 1 of 3 study drugs. The descriptive
statistics for the included participants at baseline are presented in
Table 1.
Study Medications and Assessments
Each participant was offered a study drug based on a sealed,
opaque envelope containing a list of the study drugs organized in a
random sequence. The random sequences were prepared in ad-
vance by statisticians independent of the study. The first drug in
the sequence was to be offered by the attending psychiatrist and
defined the randomization drug. In the case of inability to use
the first offered drug based on previous negative experience, the
patient was offered the second one in the sequence, with the op-
tion to choose the third drug, if the second drug could not be used
either. The distribution based on the first drug in the sequence
(randomization drug) was amisulpride (n = 44), aripiprazole
(n = 48), and olanzapine (n = 52).
The treating psychiatrist was free to determine dosing within
the following ranges as defined by the following: amisulpride
50–1200 mg/d, aripiprazole 5–30 mg/d, and olanzapine 2.5–20 mg/d.
The rationale was to allow the whole dose range for all study
drugs to mimic everyday clinical circumstances and allow for
up-titration and down-titration of doses based on the clinical pre-
sentation. The mean doses used with SDs were for amisulpride
396.9 (206.9) mg, aripiprazole 14.6 (7.0) mg, and olanzapine
12.3 (3.8) mg. The combination with other psychotropics, discon-
tinuation, and any cross-titration between antipsychotics was left
to the discretion of the treating psychiatrist. The use of additional
psychotropic drugs was generally not different between the study
drug groups. In case a participant already used an antipsychotic
agent in therapeutic dosage (>0.5 defined daily dosages) at admis-
sion, nowash-out was carried out before starting on the study drug.
This was the case in 28 patients at baseline, with the following dis-
tribution among the randomization groups: aripiprazole (n = 1),
asenapine (n = 1), olanzapine (n = 5), and quetiapine (n = 2)
for the amisulpride randomization group; aripiprazole (n = 2),
olanzapine (n = 4), quetiapine (n = 4), and risperidone (n = 2)
for the aripiprazole randomization group; and aripiprazole
(n = 3), olanzapine (n = 1), and quetiapine for the olanzapine
randomization group (n = 3). In the 3 cases where the first drug
in the randomization sequence was the same as the one the pa-
tient who was already using, the next study drug in the se-
quence was chosen. The randomization was open to both the
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participant and the clinical staff, whereas the assessments were
conducted by blinded research personnel.
The participants were assessed at baseline, 1 week, 3 weeks,
6 weeks, and 3 months, 6 months, 9 months, and 12months there-
after. All PANSS raters were trained and certified by the PANSS
Institute (panss.org) after satisfactory interrater and validity per-
formance were achieved.
The primary outcome of the present studywas change of hal-
lucinations as measured by item P3 (hallucinatory behavior) in the
PANSS positive subscale. A score of 3 or higher indicated the
presence of hallucinations.10 Participants with hallucinations at
baseline defined the hallucination (HALL) subgroup. Whereas a
threshold of 3 serves as a cutoff for presence of hallucinations
per se, a score of 4 or more indicates hallucinations where thinking
and behavior are affected, that is, psychosis being present. Sensitiv-
ity analyseswere therefore undertaken for thosewith a P3 score of 4
or higher. Although the comparisons between study drugs were un-
dertaken also in the total sample, the HALL subsample was the
main group for the primary analyses in the present study.
The participants underwent assessments using the Structured
Clinical Interview for the PANSS, the Clinical Drug and Alcohol
Use Scales,19 the “Udvalg for Kliniske Undersøgelser” Side Ef-
fects Rating Scale—Patient-Administered version,20 the Clinical
Global Impression—Severity of Illness scale (CGI-S),21 and the
Global Assessment of Functioning (GAF)—split version scores.22
Serum levels of study drugs and the use of concomitant psychotropic
medication were registered at each visit. The Calgary Depression
Scale for Schizophrenia, PANSS, CGI-S, GAF, and the “Udvalg
for Kliniske Undersøgelser” were administered at all visits.
Statistical Analyses
Statistical analyses were conducted according to intention-
to-treat (ITT) and per-protocol (PP) groups. Intention-to-treat
analysis is based on the first drug in the sequence, the randomiza-
tion drug, whereas PP analysis is based on which medication par-
ticipants chose. The ITT analyses were defined as the primary
analyses before the start of the trial, accompanied by secondary
PP analyses, as both strategies have advantages and disadvan-
tages. Intention-to-treat analyses have the main advantage of be-
ing unbiased because they are based on randomization groups.
However, patients might choose another drug than the first one
in the sequence. Thus, differences between the study drugs may
be leveled out. The PP analyses have the main advantage of being
based on the actually study drug chosen but have the disadvantage
of potential selection bias, as the randomization is no longer valid.
Thus, differences found between the study drugs may be biased.
Statistical analyses for the outcome variable were conducted
in statistical program software R23 with a linear mixed-effects
model (LME). The linear mixed-effects model is a preferred class
of models when there are missing data because of its ability to
handle both data that are missing completely at random and data
that are missing at random. A random intercept was included in
the model to account for intraindividual correlation, as each indi-
vidual had repeated measurements for the outcome variable.24
The model was fitted to investigate the level of the outcome vari-
able at all visits.
The analysis strategy was as follows: first, the analyses were
conducted in the HALL subgroup after an initial analysis in the
TABLE 1. Baseline Demographic and Clinical Characteristics for the Total Sample
Amisulpride (n = 44),
Mean (SD) or n (%)
Aripiprazole (n = 48),
Mean (SD) or n (%)
Olanzapine (n = 52),
Mean (SD) or n (%)
All (n = 144), Mean
(SD) or n (%)
Age, y 30.6 (11.7) 32.1 (13.1) 32.2 (13.3) 31.7 (12.7)
Men 28/44 (64%) 32/48 (67%) 33/52 (63%) 93/144 (65%)
White/Caucasians 39/44 (89%) 35/48 (73%) 44/52 (85%) 118/144 (82%)
Years of education 12.7 (3) 11.9 (2.8) 12.2 (2.7) 12.3 (2.8)
Living alone 21/44 (48%) 17/48 (35%) 23/52 (44%) 61/144 (42%)
Employed 14/44 (32%) 12/48 (25%) 10/52 (19%) 36/144 (25%)
Smoking 30 (68.0%) 29 (60.0%) 26 (50.0%) 85 (59.0%)
Alcohol abuse/dependence 4 (9.0%) 7 (15.0%) 2 (4.0%) 13 (9.0%)
Drug abuse/dependence 10 (23.0%) 8 (17.0%) 9 (17.0%) 27 (19.0%)
Diagnosis: schizophrenia 28/44 (64%) 27/48 (56%) 29/52 (56%) 84/144 (58%)
Diagnosis: schizotypal 1/44 (2%) 0/48 (0%) 1/52 (2%) 2/144 (1%)
Diagnosis: delusional disorder 4/44 (9%) 8/48 (17%) 9/52 (17%) 21/144 (15%)
Diagnosis: brief psychotic disorder 8/44 (18%) 3/48 (6%) 7/52 (13%) 18/144 (12%)
Diagnosis: schizoaffective 3/44 (7%) 5/48 (10%) 2/52 (4%) 10/144 (7%)
Diagnosis: other 0/44 (0%) 1/48 (2%) 0/52 (0%) 1/144 (1%)
Diagnosis: unspecified 0/44 (0%) 4/48 (8%) 4/52 (8%) 8/144 (6%)
AP− 16/44 (36%) 23/48 (48%) 17/52 (33%) 56/144 (39%)
PANSS total 80.1 (18.8) 76.6 (13.4) 78.7 (15.5) 78.4 (15.9)
PANSS positive 21.4 (4.8) 21.3 (4.9) 21 (4.7) 21.2 (4.8)
PANSS negative 18.2 (7) 17.2 (5.6) 18.1 (5.8) 17.8 (6.1)
PANSS general 40.5 (10.3) 38.1 (7.2) 39.7 (8.1) 39.4 (8.6)
CGI 5.1 (0.9) 4.9 (0.7) 5 (0.8) 5 (0.8)
GAF 36 (9.6) 36 (9.6) 35.5 (8.8) 35.8 (9.3)
CDSS 7.6 (5.7) 5.4 (4.5) 7.1 (5.1) 6.7 (5.1)
AP−, no previous exposure to antipsychotic drugs; CDSS, the Calgary Depression Scale for Schizophrenia; n, number in the total sample; n (%), number
(percent) with characteristics; Smoking, daily tobacco smokers.
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whole sample. Second, analyses for the differences among study
drugs in patients who were antipsychotic-naive (AP−) and patients
who were exposed to antipsychotic treatment before entering the
study (AP+) were conducted in the HALL subgroup. Third, the dif-
ferences for AP− and AP+ subgroups were analyzed in each study
drug, in the HALL subgroup. All steps were repeated in the sen-
sitivity analysis for patients with baseline PANSS P3 ≥4.
RESULTS
The baseline mean P3 score for the total sample was 3.64
(0.13). Discontinuation of study drug during the treatment course
and lost to follow-up rates are provided in Supplementary Mate-
rial S1, http://links.lww.com/JCP/A751.
A total of 105 patients (71.9%) scored 3 or more on the
PANSS P3 hallucinatory behavior item at baseline (HALL sub-
group). The baseline ITT distribution of study drugs at in the
HALL subgroup was amisulpride (n = 33), aripiprazole (n = 33),
and olanzapine (n = 39). The HALL subgroup was not substan-
tially different from the total sample with regard to demographic
or clinical descriptives, except for hallucinations. The descriptive
statistics for the HALL subgroup in ITT analysis is provided in
Supplementary Material 2, http://links.lww.com/JCP/A751. The
baseline mean P3 score for the HALL subgroup was 4.51 (0.14;
moderate/moderate severe). The decrease of hallucinations during
follow-up was to 2.14 (minimal), with the reduction amounting to
61%. The mean P3 scores for each visit in the total sample and in
the HALL subgroup are provided in Table 2.
Overall Analysis
Initially analyses were conducted in thewhole sample to com-
pare the study drugs on the main outcome measure P3.
No statistically significant differences among the 3 study
drugs were seen for P3 score change in the ITTanalysis, although
a trend for statistically significant less reduction in the aripiprazole
group compared with amisulpridewas seen at week 3. Per-protocol
analyses showed a lower baseline P3 score for the aripiprazole
group and less reduction in this group compared with amisulpride
at week 3 (Supplementary Material S3; Tables S3-1, S3-2, http://
links.lww.com/JCP/A751).
In the HALL subgroup, the ITTanalysis revealed a significantly
less reduction of hallucinations for participants using olanzapine
in weeks 12, 26, 39, and 52 when compared with amisulpride. A
significantly less reduction of hallucinations in the olanzapine
group was also seen when compared with aripiprazole in weeks
26 and 52 (Table 3). No significant differences were revealed in
comparisons between amisulpride and aripiprazole. In the PP anal-
ysis, no significant differences among the 3 study drugs were seen
(Supplementary Material S4, http://links.lww.com/JCP/A751).
TABLE 2. PANSS P3 Mean Scores and SD for the Total Sample
and for the HALL Subgroup
Weeks All Participants HALL Subgroup
Baseline 3.64 (0.13) 4.51 (0.14)
1 3.01 (0.13) 3.65 (0.14)
3 2.53 (0.14) 2.98 (0.15)
6 2.21 (0.15) 2.57 (0.15)
12 2.17 (0.15) 2.45 (0.16)
26 1.9 (0.17) 2.23 (0.18)
39 1.82 (0.17) 2.21 (0.18)
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Analyses for AP− and AP+ Participants
Only the HALL subgroup was chosen for further analyses.
We used the same statistical analyses separately for AP− and AP+
participants. Similar results for the ITT and the PP analyses were
seen in both subgroups. No differences among the 3 study drugs
were found for the AP− participants (Supplementary Material
S5; Tables S5–1, S5–2, http://links.lww.com/JCP/A751). In the
AP+ subgroup, there were significant differences for the P3 score
reduction between aripiprazole and amisulpride at week 3 for both
the ITT and PP analyses (P = 0.043 and 0.012, respectively). No
significant differences were seen at other time points. Olanzapine
showed significantly less reduction in the P3 score when com-
pared with amisulpride at weeks 12, 26, 39, and 52 (P = 0.001,
0.001, 0.002, and 0.023, respectively) in the ITT analysis and at
weeks 3, 12, 26, and 39 (P = 0.041, 0.015, 0.004, and 0.020, re-
spectively) in the PP analysis. Moreover, olanzapine showed less
reduction in P3 score when compared with aripiprazole at weeks
12 and 26 (P = 0.040 and 0.009, respectively) in the ITT analysis
and at week 12 (P = 0.007) in the PP analysis. Results for the ITT
analysis are shown in Table 4 and for the PP analysis in Supple-
mentary Material S6, http://links.lww.com/JCP/A751.
Analyses for Each Study Drug: AP+ Versus AP−
The same statistical approach was used for each study drug
separately. No statistically significant differences were seen be-
tween the AP− and AP+ in participants who used amisulpride or
aripiprazole, neither in the ITT nor in the PP analysis. For partic-
ipants who used olanzapine, there was a significant difference in
reduction of the P3 score between the AP− and AP+ subgroups
at week 26 for both the ITT and the PP analyses (P = 0.034 and
0.022, respectively; Fig. 1). Furthermore, there was a significant
difference at week 12 and a trend toward significance at week
39 in the PP analysis (P = 0.038 and 0.053, respectively; Supple-
mentary Material S7; Tables S7-1, S7-2, http://links.lww.com/
JCP/A751).
Sensitivity Analyses
We conducted a sensitivity analysis where patients with
PANSS P3 score ≥4 were included following the same statistical
approach. Similar results were found (Supplementary Material S8,
http://links.lww.com/JCP/A751): in the total subgroup ITTanalysis,
olanzapine showed less reduction compared with amisulpride
at weeks 12, 26, 39, and 52 (P = 0.004, 0.032, 0.025, and 0.02,
TABLE 4. ITT Analysis, HALL-Subgroup, AP+
Baseline 1 wk 3 wk 6 wk 12 wk 26 wk 39 wk 52 wk
Amisulpride
(n = 20)













































P values in bold correspond to statistical significant findings.
Numbers in the baseline column give the estimated values, and numbers in the other columns give the estimated decrease in PANSS P3 compared with
baseline. Numbers in parentheses are estimated SDs. P values in single brackets correspond to comparison to the reference drug amisulpride. P values in
double brackets correspond to comparison to aripiprazole.
FIGURE 1. Intention-to-treat analysis. Comparing AP− and AP+ participants who were randomized to olanzapine.
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respectively; Table S8-1). Differences between olanzapine and
aripiprazolewere no longer significant, although a trend for less P3 score
reduction for olanzapine in week 12was observed (Table S8-1). In
the PP analysis, there were no statistical significant differences
(Table S8-2). As in the analyses based on a P3 score threshold
≥3, no statistically significant differences were found among an-
tipsychotics for the AP− participants, neither in ITT nor in PP
analyses (Tables S8-3, S8-4). For the AP+ participants, the ITT
analysis revealed less reduction for olanzapine compared with
amisulpride at weeks 12, 26, 39, and 52 (P = 0.001, 0.003,
0.025, 0.004, and 0.025, respectively) and less reduction for
olanzapine compared with aripiprazole at week 26 (P = 0.021;
Table S8-5). The PP analysis revealed less reduction in the
olanzapine group compared with amisulpride at weeks 3, 12,
and 26 (P = 0.037, 0.021, and 0.015, respectively) and less reduc-
tion in the olanzapine group compared with aripiprazole at week
12 (P = 0.01; Table S8-6). As in the separate analyses for P3 ≥ 3
of each study drug, statistically significant results were only
found for olanzapine in the P3 ≥ 4 analyses. In the ITT analyses
of olanzapine, the AP− participants had greater P3 score reduc-
tions than did AP+ participants in weeks 26 and 39 (P = 0.044
and 0.05). In the PP analyses, statistically significant differences
were reached at weeks 12, 26, and 39 (P = 0.046, 0.031, and
0.024, respectively; Tables S8-7, S8-8).
DISCUSSION
The main objective of the study was to investigate differences
in effectiveness among 3 pharmacologically different antipsychotics
for reduction of hallucinations. The study showed differential effec-
tiveness for participants who had used antipsychotics before enter-
ing the study, whereas no differenceswere seen in AP− participants.
A faster decrease of hallucinations appeared in the amisulpride
group at 3 weeks compared with aripiprazole in both the ITT and
the PP analyses and to olanzapine in the PP analysis. The finding
of earlier response to amisulpride might theoretically be biased by
differences in the doses, as amisulpride is normally up-titrated more
quickly than olanzapine. However, this was not the case in our
study, where the olanzapine dose was in fact relatively higher than
amisulpride and aripiprazole at 3 weeks.
The most consistent differences between the study drugs ap-
peared later in the treatment.
The study shows that hallucinations in general respond well
and rapidly to antipsychotic treatment. For participants with clin-
ically significant hallucinations, the symptom had decreased to
“mild” according to PANSS P3 after 3 weeks and continued to de-
crease throughout the follow-up period. This finding is consistent
with our previous findings, where 80% of patients with clinically
significant hallucinations at baseline were found to be “dramatic”
responders, with extinction of hallucinations during the first 4
weeks of treatment.11 The present results are also in linewith find-
ings from Sommer et al10 where first-episode schizophrenia pa-
tients showed a mean reduction of hallucinations from 4.4 at
baseline to 2.5 after 4 weeks of treatment measured by the PANSS
P3 item.
Most studies investigating drug differences have used the total
psychopathology score from the PANSS questionnaire or symptom
clusters as outcome measures. The meta-analysis by Huhn et al3
reveals gradual differences in effect sizes when comparing 32 an-
tipsychotic drugs in multiepisode schizophrenia patients. The re-
sults showed that both amisulpride and olanzapine were among
the most efficacious antipsychotics, whereas aripiprazole seemed
to be less effective. However, a meta-analysis by Rutherford et al25
showed that over time, there was a placebo-effect increase, together
with an active medication-effect decrease. Thus, the smaller effect
of aripiprazole compared with the 2 other antipsychotics in the
meta-analysis may be at least in part explained by the fact that the
aripiprazole studies have been conducted in more recent years.
None of the studies included in the meta-analysis by Huhn
et al3 focused on hallucinations specifically. However, Sommer
et al10 used data from the EUFEST trial where first-episode psy-
chosis (FEP) patients were followed up for 1 year. The authors
found that all the included atypical antipsychotics were equally ef-
fective against hallucinations, but haloperidolwas slightly inferior.
Almost half of our sample was AP− at inclusion, which may be
considered a proxy for FEP. When analyzing this subgroup sepa-
rately, no statistically significant differences were found among
the study drugs. Thus, our study contributes to existing evidence
that the antihallucinatory effectiveness among atypical antipsy-
chotics for the subgroup of patients in an early stage of psychosis
may be equal. A possible explanation may be that in this particular
group, “everything works” because they are generally highly re-
sponsive to antipsychotic medication, whereas inmultiepisode pa-
tients, where the drug response generally is poorer, probably also
because the proportion of patients with more severe disorder is
higher, the separate drugs are subject to a tougher test. Thus, dif-
ferences in the effectiveness of antipsychotic drugs may appear. A
previous study from our group has also shown that ziprasidone
and quetiapine were superior to risperidone in reducing hallucina-
tions, with olanzapine in an intermediate position. In this random-
ized controlled trial, patients were followed up for up to 2 years.12
In the present study, olanzapine was less effective for reduction
of hallucinations compared with amisulpride and, at some time
points, also less effective compared with aripiprazole. This finding
seems to be driven by the participants previously exposed to anti-
psychotics, as statistically significant differences were only seen
in the AP+ subgroup.
Olanzapine is generally found to be among the most effica-
cious drugs,3 so the reduced effect compared with the other 2 study
drugs in participants previously treated with antipsychotics was un-
expected. However, as discussed previously, most of the antipsy-
chotic studies have measured the effect or effectiveness of drug
treatment on PANSS total psychopathology or total subscale scores.
Thus, it is possible that the effect of olanzapine seen in other studies
may be primarily the result of an effect on other positive symptoms
than hallucinations. For example, delusions are assessed in 3 of 7
items in the PANSS positive subscale, whereas hallucinations are
assessed in only 1. Accordingly, the weight of any change of hallu-
cinations may theoretically be buried under changes of delusions.
A mechanistic explanation for the inferiority of effect for
olanzapine compared with amisulpride and aripiprazole in the
AP+ subgroup could be related to differences in prefrontal cortex
activation. It is suggested in the neurocognitive model of halluci-
nations26 that this is the result of unbalanced hyperactivation
in the temporal lobe not sufficiently inhibited by frontotempo-
ral projections because of prefrontal hypoactivation. Limited
evidence also shows that both amisulpride and aripiprazole ac-
tivate prefrontal cortex, whereas for olanzapine, the results are
more conflicting.27–31 Olanzapine impairs some cognitive func-
tions; thus, possibly prefrontal also cortical activation may be
low because of its sedating effects via blockade of muscarinergic,
histaminergic, and adrenergic receptors. If the antihallucinatory
response partly depends on activation of prefrontal cortex, then
differential prefrontal cortical impairment could hypothetically
contribute to the superiority of amisulpride and aripiprazole over
olanzapine. Because cognitive activation is found to be reduced
in more chronic patients and because the difference among anti-
psychotics appears only in AP+ participants, it could suggest that
prefrontal activity is more sensitive to antipsychotics only in pa-
tients with reduced prefrontal cortex activity.
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Limitations
Some limitations should be mentioned. The pragmatic de-
sign of the study allows for fewer exclusion criteria, thus possibly
resulting in a more heterogeneous sample. However, such a study
design mimics “real life,” and the results can therefore be
interpreted in the light of a daily clinical setting. The decision to
allow for the change of antipsychotic treatment regime over the
course of the study may have affected our results. However, the
small number of participants who changed treatment regime
makes this a less likely possibility. A high attrition rate is also a
concern, which is a major problem in all antipsychotic trials.32
A sensitivity analysis showed that using themissing-at-random as-
sumption in the statistical analyses is plausible, both for the total
sample and for the HALL subgroup. Total attrition was not asso-
ciated with any of the demographic variables and did not exceed
the rate found in other studies. Use of concomitant drugs might
be considered as a limitation. However, there were generally no
differences among the groups, and it was not considered to influ-
ence the results.
Our choice to include in the main analyses participants with
P3 score ≥3 might be seen as a limitation because a score of 3 is
considered below the psychosis threshold. However, a score of 3
in the PANSS scoring manual is described as “hallucinations or
abnormal perceptual experiences that does not affect thinking or
behavior,” so even at subthreshold levels for psychosis, a score
of 3 remains a symptom frequently present in psychotic popula-
tions. Considering that subpsychosis levels of symptoms have
shown brain activation in functional magnetic resonance imaging
studies, this threshold was chosen to better capture potential dif-
ferences of antipsychotics, which theoretically would act partly
via different neurotransmitter systems. However, we conducted
sensitivity analyses in addition, where participants with P3 ≥ 4
were included. Interestingly, similar result were present where
olanzapine showed less reduction for hallucinations in participants
previously treated with antipsychotics, mainly when compared
with amisulpride.
We did not correct for multiple comparisons, which might in-
crease the chance for false-positive results. However, the statistical
significant results seemed to follow an internally consistent pat-
tern throughout the study until 52 weeks and were therefore by
far more common and consistent than would have been expected
to occur by chance.
Despite the relatively large number of participants and direct
comparison of antipsychotics, our results should be interpreted
with caution before independently replicated.
Conclusions
Hallucinations respond fairly well to antipsychotics. Differ-
ential antihallucinatory effectiveness was found for the 3 study
drugs, but this was seen only in participants exposed to antipsy-
chotic treatment before entering the study, whereas no significant
differences were found for the AP− participants.
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